Statins Do Not Decrease the Risk for Wet Age-Related Macular Degeneration

REFERENCES

• Klein R, Klein B E, Jensen S C. The relation of cardiovascular disease and its risk factors to the 5-year incidence of age-related maculopathy: The Beaver Dam Eye Study. Ophthalmology 1997; 104: 1804–1812
   PubMed Web of Science ®Google Scholar
• Klein R, Klein B E, Linton K L. Prevalence of age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology 1992; 99: 933–943
   PubMed Web of Science ®Google Scholar
• Leibowitz H M, Krueger D E, Maunder L R, et al. The Framingham Eye Study monograph: An ophthalmological and epidemiological study of cataract, glaucoma, diabetic retinopathy, macular degeneration, and visual acuity in a general population of 2631 adults, 1973–1975. Surv Ophthalmol 1980; 24: 335–610
   PubMedGoogle Scholar
• Klein R, Klein B E, Jensen S C, et al. Medication use and the 5-year incidence of early age-related maculopathy: The Beaver Dam Eye Study. Arch Ophthalmol 2001; 119: 1354–1359
   PubMed Web of Science ®Google Scholar
• van Leeuwen R, Ikram M K, Vingerling J R, Witteman J C, Hofman A, de Jong P T. Blood pressure, atherosclerosis, and the incidence of age-related maculopathy: The Rotterdam Study. Invest Ophthalmol Vis Sci 2003; 44: 3771–3777
   PubMed Web of Science ®Google Scholar
• Risk factors associated with age-related macular degeneration. A case-control study in the age-related eye disease study: Age-Related Eye Disease Study Report No. 3. Ophthalmology 2000; 107: 2224–2232
   PubMed Web of Science ®Google Scholar
• Hyman L, Schachat A P, He Q, Leske M C. Hypertension, cardiovascular disease, and age-related macular degeneration. Age-Related Macular Degeneration Risk Factors Study Group. Arch Ophthalmol 2000; 118: 351–358
   PubMed Web of Science ®Google Scholar
• Kaiserman I, Kaiserman N, Elhayany A, Vinker S. Risk factors for photodynamic therapy of predominantly classic choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 2006; 142: 441–447
   PubMed Web of Science ®Google Scholar
• Clemons T E, Milton R C, Klein R, Seddon J M, Ferris F L, III. Risk factors for the incidence of advanced age-related macular degeneration in the Age-Related Eye Disease Study (AREDS)—AREDS Report No. 19. Ophthalmology 2005; 112: 533–539
   PubMed Web of Science ®Google Scholar
• McCarty C A, Mukesh B N, Fu C L, Mitchell P, Wang J J, Taylor H R. Risk factors for age-related maculopathy: The Visual Impairment Project. Arch Ophthalmol 2001; 119: 1455–1462
   PubMed Web of Science ®Google Scholar
• Schaumberg D A, Christen W G, Hankinson S E, Glynn R J. Body mass index and the incidence of visually significant age-related maculopathy in men. Arch Ophthalmol 2001; 119: 1259–1265
   PubMedGoogle Scholar
• Cruickshanks K J, Klein R, Klein B E, Nondahl D M. Sunlight and the 5-year incidence of early age-related maculopathy: The Beaver Dam Eye Study. Arch Ophthalmol 2001; 119: 246–250
   PubMedGoogle Scholar
• Delcourt C, Michel F, Colvez A, Lacroux A, Delage M, Vernet M H. Associations of cardiovascular disease and its risk factors with age-related macular degeneration: The POLA Study. Ophthalmic Epidemiol 2001; 8: 237–249
   PubMedGoogle Scholar
• Wachter A, Sun Y, Dasch B, Krause K, Pauleikhoff D, Hense H W. Munster age and retina study (MARS). Association between risk factors for arteriosclerosis and age-related macular degeneration. Ophthalmologe 2004; 101: 50–53
   PubMed Web of Science ®Google Scholar
• Belda Sanchis J I, Quijada Gonzalez A, Munoz Ruiz G, Rodriguez Galietero A, Romero Gomez F J, Diaz Llopis M. Are blood lipids a risk factor for age-related macular degeneration?. Arch Soc Esp Oftalmol 2001; 76: 13–17
   PubMedGoogle Scholar
• Genest J J, McNamara J R, Salem D N, Schaefer E J. Prevalence of risk factors in men with premature coronary artery disease. Am J Cardiol 1991; 67: 1185–1189
   PubMed Web of Science ®Google Scholar
• Clinical Practice Recommendations 2005. Diabetes Care 2005; 28(Suppl 1)S1–79
   PubMedGoogle Scholar
• Tomany S C, Wang J J, Van Leeuwen R, et al. Risk factors for incident age-related macular degeneration: Pooled findings from 3 continents. Ophthalmology 2004; 111: 1280–1287
   PubMed Web of Science ®Google Scholar
• Miyazaki M, Kiyohara Y, Yoshida A, Iida M, Nose Y, Ishibashi T. The 5-year incidence and risk factors for age-related maculopathy in a general Japanese population: The Hisayama Study. Invest Ophthalmol Vis Sci 2005; 46: 1907–1910
   PubMed Web of Science ®Google Scholar
• Hennekens C H. Current perspectives on lipid lowering with statins to decrease risk of cardiovascular disease. Clin Cardiol 2001; 24: Ii-2–5
   Web of Science ®Google Scholar
• Miller L J, Chacko R. The role of cholesterol and statins in Alzheimer's disease. Ann Pharmacother 2004; 38: 91–98
   PubMed Web of Science ®Google Scholar
• Bauer D C, Mundy G R, Jamal S A, et al. Use of statins and fracture: Results of four prospective studies and cumulative meta-analysis of observational studies and controlled trials. Arch Intern Med 2004; 164: 146–152
   PubMed Web of Science ®Google Scholar
• Werner N, Nickenig G, Laufs U. Pleiotropic effects of HMG-CoA reductase inhibitors. Basic Res Cardiol 2002; 97: 105–116
   PubMed Web of Science ®Google Scholar
• Curcio C A, Millican C L, Bailey T, Kruth H S. Accumulation of cholesterol with age in human Bruch's membrane. Invest Ophthalmol Vis Sci 2001; 42: 265–274
   PubMed Web of Science ®Google Scholar
• Malek G, Li C M, Guidry C, Medeiros N E, Curcio C A. Apolipoprotein B in cholesterol-containing drusen and basal deposits of human eyes with age-related maculopathy. Am J Pathol 2003; 162: 413–425
   PubMed Web of Science ®Google Scholar
• Hall N F, Gale C R, Syddall H, Phillips D I, Martyn C N. Risk of macular degeneration in users of statins: Cross-sectional study. Br Med J 2001; 323: 375–376
   PubMed Web of Science ®Google Scholar
• McGwin G, Jr, Xie A, Owsley C. The use of cholesterol-lowering medications and age-related macular degeneration. Ophthalmology 2005; 112: 488–494
   PubMed Web of Science ®Google Scholar
• McGwin G, Jr, Owsley C, Curcio C A, Crain R J. The association between statin use and age-related maculopathy. Br J Ophthalmol 2003; 87: 1121–1125
   PubMed Web of Science ®Google Scholar
• McCarty C A, Mukesh B N, Guymer R H, Baird P N, Taylor H R. Cholesterol-lowering medications reduce the risk of age-related maculopathy progression. Med J Aust 2001; 175: 340
   PubMed Web of Science ®Google Scholar
• Wilson H L, Schwartz D M, Bhatt H R, McCulloch C E, Duncan J L. Statin and aspirin therapy are associated with decreased rates of choroidal neovascularization among patients with age-related macular degeneration. Am J Ophthalmol 2004; 137: 615–624
   PubMed Web of Science ®Google Scholar
• Klein R, Klein B E, Tomany S C, Danforth L G, Cruickshanks K J. Relation of statin use to the 5-year incidence and progression of age-related maculopathy. Arch Ophthalmol 2003; 121: 1151–1155
   PubMed Web of Science ®Google Scholar
• van Leeuwen R, Vingerling J R, Hofman A, de Jong P T, Stricker B H. Cholesterol lowering drugs and risk of age related maculopathy: Prospective cohort study with cumulative exposure measurement. Br Med J 2003; 326: 255–256
   PubMed Web of Science ®Google Scholar
• Smeeth L, Cook C, Chakravarthy U, Hubbard R, Fletcher A E. A case control study of age related macular degeneration and use of statins. Br J Ophthalmol 2005; 89: 1171–1175
   PubMed Web of Science ®Google Scholar
• Hogg R E, Woodside J V, Gilchrist S E, et al. Cardiovascular disease and hypertension are strong risk factors for choroidal neovascularization. Ophthalmology 2008; 115: 1046–1052
   PubMed Web of Science ®Google Scholar
• Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: One-year results of two randomized clinical trials—TAP Report. Arch Ophthalmol 1999; 117: 1329–1345
   PubMed Web of Science ®Google Scholar
• Barbazetto I, Burdan A, Bressler N M, et al. Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin: Fluorescein angiographic guidelines for evaluation and treatment—TAP and VIP Report No. 2. Arch Ophthalmol 2003; 121: 1253–1268
   PubMedGoogle Scholar
• Rennert G, Peterburg Y. Prevalence of selected chronic diseases in Israel. Isr Med Assoc J 2001; 3: 404–408
   PubMed Web of Science ®Google Scholar
• van Leeuwen R, Tomany S C, Wang J J, et al. Is medication use associated with the incidence of early age-related maculopathy? Pooled findings from three continents. Ophthalmology 2004; 111: 1169–1175
   PubMed Web of Science ®Google Scholar